 Tacrolimus
"Tacrolimus" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A macrolide isolated from the culture broth of a strain of Streptomyces tsukubaensis that has strong immunosuppressive activity in vivo and prevents the activation of T-lymphocytes in response to antigenic or mitogenic stimulation in vitro.
| Descriptor ID |
D016559
|
| MeSH Number(s) |
D02.540.505.810
|
| Concept/Terms |
Prograf- Prograf
- Fujisawa Brand of Tacrolimus
- Prograft
- Cilag Brand of Tacrolimus
- Janssen Brand of Tacrolimus
Anhydrous Tacrolimus- Anhydrous Tacrolimus
- Tacrolimus, Anhydrous
- Tacrolimus Anhydrous
- Anhydrous, Tacrolimus
|
Below are MeSH descriptors whose meaning is more general than "Tacrolimus".
Below are MeSH descriptors whose meaning is more specific than "Tacrolimus".
This graph shows the total number of publications written about "Tacrolimus" by people in UAMS Profiles by year, and whether "Tacrolimus" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2022 | 1 | 0 | 1 | | 2021 | 1 | 0 | 1 | | 2020 | 2 | 1 | 3 | | 2019 | 2 | 1 | 3 | | 2018 | 0 | 1 | 1 | | 2016 | 0 | 2 | 2 | | 2015 | 0 | 2 | 2 | | 2014 | 3 | 0 | 3 | | 2013 | 1 | 1 | 2 | | 2012 | 1 | 2 | 3 | | 2011 | 0 | 1 | 1 | | 2010 | 0 | 1 | 1 | | 2009 | 0 | 1 | 1 | | 2008 | 0 | 1 | 1 | | 2007 | 0 | 1 | 1 | | 2006 | 1 | 0 | 1 | | 2004 | 1 | 2 | 3 | | 2003 | 1 | 1 | 2 | | 2002 | 1 | 0 | 1 | | 2001 | 3 | 1 | 4 |
To return to the timeline, click here.
Below are the most recent publications written about "Tacrolimus" by people in Profiles over the past ten years.
-
Hoy MJ, Park E, Lee H, Lim WY, Cole DC, DeBouver ND, Bobay BG, Pierce PG, Fox D, Ciofani M, Juvvadi PR, Steinbach W, Hong J, Heitman J. Structure-Guided Synthesis of FK506 and FK520 Analogs with Increased Selectivity Exhibit In Vivo Therapeutic Efficacy against Cryptococcus. mBio. 2022 06 28; 13(3):e0104922.
-
Gobeil SM, Bobay BG, Juvvadi PR, Cole DC, Heitman J, Steinbach WJ, Venters RA, Spicer LD. Leveraging Fungal and Human Calcineurin-Inhibitor Structures, Biophysical Data, and Dynamics To Design Selective and Nonimmunosuppressive FK506 Analogs. mBio. 2021 12 21; 12(6):e0300021.
-
Madsen S, Price KN, Shi VY, Lio PA. Pearls in Mitigating Application Pain of Topical Nonsteroidal Agents. Dermatology. 2020; 236(5):477-480.
-
Juvvadi PR, Bobay BG, Gobeil SMC, Cole DC, Venters RA, Heitman J, Spicer LD, Steinbach WJ. FKBP12 dimerization mutations effect FK506 binding and differentially alter calcineurin inhibition in the human pathogen Aspergillus fumigatus. Biochem Biophys Res Commun. 2020 05 21; 526(1):48-54.
-
Davis LE, Tripathi S. Neuropsychiatric Complications of Immunosuppressants: A Case Report of Tacrolimus-Induced Catatonia in a Liver Transplant Recipient. Prim Care Companion CNS Disord. 2020 01 09; 22(1).
-
Mata E, Loh TY, Ludwig C, Price KN, Fernandez JM, Krase JM, Shi VY. Pharmacy costs of systemic and topical medications for atopic dermatitis. J Dermatolog Treat. 2021 Aug; 32(5):514-516.
-
Juvvadi PR, Fox D, Bobay BG, Hoy MJ, Gobeil SMC, Venters RA, Chang Z, Lin JJ, Averette AF, Cole DC, Barrington BC, Wheaton JD, Ciofani M, Trzoss M, Li X, Lee SC, Chen YL, Mutz M, Spicer LD, Schumacher MA, Heitman J, Steinbach WJ. Harnessing calcineurin-FK506-FKBP12 crystal structures from invasive fungal pathogens to develop antifungal agents. Nat Commun. 2019 09 19; 10(1):4275.
-
Sood AK, McShane DB, Googe PB, Wu EY. Successful Treatment of PAPA Syndrome with Dual Adalimumab and Tacrolimus Therapy. J Clin Immunol. 2019 11; 39(8):832-835.
-
Fridell JA, Mangus RS, Chen JM, Taber TE, Cabrales AE, Sharfuddin AA, Yaqub MS, Powelson JA. Steroid-free three-drug maintenance regimen for pancreas transplant alone: Comparison of induction with rabbit antithymocyte globulin +/- rituximab. Am J Transplant. 2018 12; 18(12):3000-3006.
-
Juvvadi PR, Lee SC, Heitman J, Steinbach WJ. Calcineurin in fungal virulence and drug resistance: Prospects for harnessing targeted inhibition of calcineurin for an antifungal therapeutic approach. Virulence. 2017 02 17; 8(2):186-197.
-
Juvvadi PR, Pemble CW, Ma Y, Steinbach WJ. Novel motif in calcineurin catalytic subunit is required for septal localization of calcineurin in Aspergillus fumigatus. FEBS Lett. 2016 Feb; 590(4):501-8.
-
Falloon K, Juvvadi PR, Richards AD, Vargas-Muñiz JM, Renshaw H, Steinbach WJ. Characterization of the FKBP12-Encoding Genes in Aspergillus fumigatus. PLoS One. 2015; 10(9):e0137869.
-
Kim D, Kim I, Wang J, White C, Carroll JL. Hydrogen sulfide and hypoxia-induced changes in TASK (K2P3/9) activity and intracellular Ca(2+) concentration in rat carotid body glomus cells. Respir Physiol Neurobiol. 2015 Aug 15; 215:30-8.
-
Shi VY, Joo JS, Sharon VR. Multiple labial melanotic macules occurring after topical application of calcineurin inhibitors. Dermatol Online J. 2014 Aug 17; 20(8).
-
Pereira MJ, Palming J, Rizell M, Aureliano M, Carvalho E, Svensson MK, Eriksson JW. Cyclosporine A and tacrolimus reduce the amount of GLUT4 at the cell surface in human adipocytes: increased endocytosis as a potential mechanism for the diabetogenic effects of immunosuppressive agents. J Clin Endocrinol Metab. 2014 Oct; 99(10):E1885-94.
-
Parks AC, Conner KJ, Armstrong CA. Long-term clearance of linear porokeratosis with tacrolimus, 0.1%, ointment. JAMA Dermatol. 2014 Feb; 150(2):194-6.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|